Immupharma (IMM)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

1.59p
   
  • Change Today:
      0.030p
  • 52 Week High: 2.61
  • 52 Week Low: 0.85
  • Currency: UK Pounds
  • Shares Issued: 416.44m
  • Volume: 181,321
  • Market Cap: £6.62m
  • RiskGrade: 328

Growth Ratings

EPS Growth shows the relative growth of a company's earnings over the last year.

The rise in total monies receivable for goods / services sold before expenses.

1yr EPS Growth Not Available
1yr Revenue Growth Not Available

Income Ratings

The percentage of the share price that a company pays out as dividends over a year.

The percentage change from the previous year in the dividend paid on each share.

Dividend Yield Not Available
1yr DPS Growth Not Available

Valuation Ratings

The share price as a ratio of revenue per share.

The share price as a ratio of net asset value.

Price Sales Ratio Not Available
Price Book Ratio
85.71% below the market average85.71% below the market average85.71% below the market average85.71% below the market average85.71% below the market average
57.14% below the sector average57.14% below the sector average57.14% below the sector average57.14% below the sector average57.14% below the sector average

Performance Ratings

In percentage total change in share price over 30 days.

In percentage total change in share price over 3 months.

Price Chg 30d
78.91% below the market average78.91% below the market average78.91% below the market average78.91% below the market average78.91% below the market average
64% below the sector average64% below the sector average64% below the sector average64% below the sector average64% below the sector average
Price Chg 3m
51.61% below the market average51.61% below the market average51.61% below the market average51.61% below the market average51.61% below the market average
20% below the sector average20% below the sector average20% below the sector average20% below the sector average20% below the sector average

Technical Ratings

The Relative Strength Index measures a share price relative to itself and its recent history.

Momentum is an oscillator that measures the rate of price change.

RSI
42.96% below the market average42.96% below the market average42.96% below the market average42.96% below the market average42.96% below the market average
52.17% below the sector average52.17% below the sector average52.17% below the sector average52.17% below the sector average52.17% below the sector average
Momentum 20
1.38% below the market average1.38% below the market average1.38% below the market average1.38% below the market average1.38% below the market average
13.04% below the sector average13.04% below the sector average13.04% below the sector average13.04% below the sector average13.04% below the sector average

Management Ratings

Operating Margin is profit as a percentage of sales.

Return on capital employed measures the return from invested and borrowed capital.

Operating Margin Not Available
ROCE Not Available

Profitability Ratings

Earnings per share, the company's profitability expressed on a per share basis.

Analysts' estimates of future EPS for the next 2 years.

EPS
47.78% below the market average47.78% below the market average47.78% below the market average47.78% below the market average47.78% below the market average
10.20% above the sector average10.20% above the sector average10.20% above the sector average10.20% above the sector average10.20% above the sector average
Forecast EPS Not Available

Profit/Loss Ratings

Monies produced from sales of goods and services after trade discounts, VAT, etc.

Operating Profit is the profit after deducting operating costs from gross profits.

Turnover Not Available
Operating Profit Loss
62.11% below the market average62.11% below the market average62.11% below the market average62.11% below the market average62.11% below the market average
10.20% above the sector average10.20% above the sector average10.20% above the sector average10.20% above the sector average10.20% above the sector average

Balance Sheet Ratings

The difference between current assets and current liabilities.

A current asset representing the company's financial liquidity.

Assets
80.71% below the market average80.71% below the market average80.71% below the market average80.71% below the market average80.71% below the market average
74.47% below the sector average74.47% below the sector average74.47% below the sector average74.47% below the sector average74.47% below the sector average
Cash
83.33% below the market average83.33% below the market average83.33% below the market average83.33% below the market average83.33% below the market average
79.59% below the sector average79.59% below the sector average79.59% below the sector average79.59% below the sector average79.59% below the sector average

Director Deal Ratings

The cumulative amount of stocks sold by company directors over 1 year

The cumulative amount of stocks bought by company directors over 1 year

Sells 1y Not Available
Buys 1y Not Available

Broker Ratings

The percentage of stockbrokers that rate the company as a Buy

The percentage of stockbrokers that rate the company as a Hold

Brokers Percent Buy Not Available
Brokers Percent Neutral Not Available

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Immupharma Market Data

Currency UK Pounds
Share Price 1.59p
Change Today 0.030p
% Change 1.92 %
52 Week High 2.61
52 Week Low 0.85
Volume 181,321
Shares Issued 416.44m
Market Cap £6.62m
RiskGrade 328

Immupharma Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
71.13% below the market average71.13% below the market average71.13% below the market average71.13% below the market average71.13% below the market average
40% below the sector average40% below the sector average40% below the sector average40% below the sector average40% below the sector average
Price Trend
62.97% below the market average62.97% below the market average62.97% below the market average62.97% below the market average62.97% below the market average
22.45% below the sector average22.45% below the sector average22.45% below the sector average22.45% below the sector average22.45% below the sector average
Income Not Available
Growth Not Available

Immupharma Dividends

No dividends found

Trades for 31-Oct-2024

Time Volume / Share Price
16:35 2,000 @ 1.59p
16:35 2,000 @ 1.59p
16:29 12,174 @ 1.61p
16:04 22,215 @ 1.59p
15:43 5,000 @ 1.59p

Immupharma Key Personnel

CEO Timothy Paul McCarthy

Top of Page